Why is Beryl Drugs falling/rising?

As of 08-Sep, Beryl Drugs Ltd is experiencing a price increase, with its current price at 24.85, reflecting a change of 0.84 or 3.5% upward. Despite this positive movement today, the stock has underperformed in the short term, with a 1-week return of -6.23% compared to the Sensex's gain of 0.53%. The stock's performance today has outperformed its sector by 3.63%, although it is trading below its 5-day and 200-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 68.36% against the 5-day average. The stock is currently trading at a discount compared to its peers, which may attract some investors despite its negative returns over the past year, where it has declined by 35.57% while profits have also fallen by 37%.
In the broader market context, Beryl Drugs' recent price increase occurs amidst a backdrop of weak long-term fundamentals, as indicated by an average Return on Capital Employed (ROCE) of 7.27% and poor growth metrics. The stock has significantly underperformed the market over the past year, with a return of -35.57% compared to the BSE500's decline of only -3.07%. This stark contrast highlights the challenges the company faces, including weak sales growth and a low EBIT to Interest ratio, which raises concerns about its ability to service debt. Overall, while the stock has shown a positive movement today, the underlying fundamentals and broader market performance suggest caution for potential investors.